97 related articles for article (PubMed ID: 17662692)
41. Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.
Milo LJ; Lai JH; Wu W; Liu Y; Maw H; Li Y; Jin Z; Shu Y; Poplawski SE; Wu Y; Sanford DG; Sudmeier JL; Bachovchin WW
J Med Chem; 2011 Jul; 54(13):4365-77. PubMed ID: 21634429
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
43. Repeated intermittent administration of a ubiquitous proteasome inhibitor leads to restrictive cardiomyopathy.
Wang X
Eur J Heart Fail; 2013 Jun; 15(6):597-8. PubMed ID: 23639782
[No Abstract] [Full Text] [Related]
44. Dismounting the MDR horse.
Libby E; Hromas R
Blood; 2010 Nov; 116(20):4037-8. PubMed ID: 21088139
[No Abstract] [Full Text] [Related]
45. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
Dutta D; Liu J; Wen K; Kurata K; Fulciniti M; Gulla A; Hideshima T; Anderson KC
Blood Cancer J; 2023 Dec; 13(1):184. PubMed ID: 38072962
[TBL] [Abstract][Full Text] [Related]
46. Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance.
Leonardo-Sousa C; Carvalho AN; Guedes RA; Fernandes PMP; Aniceto N; Salvador JAR; Gama MJ; Guedes RC
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408601
[TBL] [Abstract][Full Text] [Related]
47. The Relationship of
Zmorzynski S; Wojcierowska-Litwin M; Popek-Marciniec S; Szudy-Szczyrek A; Styk W; Chocholska S; Filip AA
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830558
[TBL] [Abstract][Full Text] [Related]
48. Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma.
Mynott RL; Wallington-Beddoe CT
ACS Pharmacol Transl Sci; 2021 Jun; 4(3):1050-1065. PubMed ID: 34151200
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.
Mynott RL; Wallington-Beddoe CT
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):713-729. PubMed ID: 33860196
[TBL] [Abstract][Full Text] [Related]
50. Pyrrolidinedithiocarbamic Acid Ammonium Salt Inhibits Apoptosis and Phenotypic Transformation of Co-Culture of Myeloma Cells and Renal Tubular Epithelial Cells by Reducing the Secretion of Light Chain Protein.
Yu X; Bao J; Cui X; DU F; Wang Y; Bi L; Sun J; Li L
Iran J Public Health; 2020 Nov; 49(11):2078-2086. PubMed ID: 33708728
[TBL] [Abstract][Full Text] [Related]
51. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.
Mofers A; Perego P; Selvaraju K; Gatti L; Gullbo J; Linder S; D'Arcy P
PLoS One; 2019; 14(10):e0223807. PubMed ID: 31639138
[TBL] [Abstract][Full Text] [Related]
52. Folate-targeted pH-sensitive bortezomib conjugates for cancer treatment.
Liu Y; Dai Z; Wang J; Tu Y; Zhu L
Chem Commun (Camb); 2019 Apr; 55(29):4254-4257. PubMed ID: 30901007
[TBL] [Abstract][Full Text] [Related]
53. Synergistic Effects of Bortezomib-OV Therapy and Anti-Invasive Strategies in Glioblastoma: A Mathematical Model.
Kim Y; Lee J; Lee D; Othmer HG
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30781871
[TBL] [Abstract][Full Text] [Related]
54. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
[TBL] [Abstract][Full Text] [Related]
55. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
56. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
Muz B; Kusdono HD; Azab F; de la Puente P; Federico C; Fiala M; Vij R; Salama NN; Azab AK
Leuk Lymphoma; 2017 Dec; 58(12):2916-2925. PubMed ID: 28509582
[TBL] [Abstract][Full Text] [Related]
57. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
Deshmukh RR; Kim S; Elghoul Y; Dou QP
J Cell Biochem; 2017 May; 118(5):1239-1248. PubMed ID: 27813130
[TBL] [Abstract][Full Text] [Related]
58. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ
J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784
[TBL] [Abstract][Full Text] [Related]
59. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
60. CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy.
Foran E; Kwon DY; Nofziger JH; Arnold ES; Hall MD; Fischbeck KH; Burnett BG
Neurobiol Dis; 2016 Apr; 88():118-24. PubMed ID: 26792401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
